⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Statins and Breast Cancer Biomarkers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Statins and Breast Cancer Biomarkers

Official Title: Statins and Breast Cancer Biomarkers

Study ID: NCT00914017

Conditions

Breast Cancer

Interventions

Atorvastatin
Placebo

Study Description

Brief Summary: There is laboratory evidence that cholesterol lowering medications (statins) inhibit the growth of breast cancer cells. Clinical studies are controversial but some show that women taking statins are less likely to get breast cancer. This ongoing randomized trial compares one-year of atorvastatin (Lipitor™) or placebo for lowering mammography-defined breast density and other surrogate markers associated with breast cancer risk.

Detailed Description: This project was designed to evaluate the effect of a specific statin (atorvastatin) on several breast cancer biomarkers. One hundred women will be treated for one year with either 40 mg of atorvastatin or placebo. The primary aim of this project is to determine the effect of atorvastatin on breast density, a known risk factor for breast cancer. In addition, the affect of atorvastatin on serum biomarkers (IGF1) and tissue biomarkers (atypia and Ki67) associated with risk is being evaluated. Because of their tolerability and safety, statins have a great potential as a breast cancer preventative agent. Should this pilot study show a significant decrease in breast density and/or change in serum and tissue biomarkers in statin treated patients these data would then be used to support a large randomized trial. This is a multi-center, prospective, randomized placebo controlled clinical trial. Target enrollment is 100 women, with 50 receiving atorvastatin and 50 receiving a similar appearing placebo tablet. Eligible women must be at least 35 years old with regular menstrual cycles and a Gail Model risk of greater than 1.66% over 5 years.

Eligibility

Minimum Age: 35 Years

Eligible Ages: ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

University of California, San Francisco, San Francisco, California, United States

Delaware Christiana Care CCOP, Helen F. Graham Cancer Center, Newark, Delaware, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States

Duke University, Durham, North Carolina, United States

Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States

Vermont Cancer Center, Burlington, Vermont, United States

Contact Details

Name: Marie E Wood, MD

Affiliation: University of Vermont

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: